Results
Title

Exendin‐4 analogs in insulinoma theranostics.

Authors

Jansen, Tom.J.P.; Lith, Sanne.A.M.; Boss, Marti; Brom, Maarten; Joosten, Lieke; Béhé, Martin; Buitinga, Mijke; Gotthardt, Martin

Abstract

Insulinomas are neuroendocrine tumors arising from the pancreatic beta cells. Currently, surgical resection is the therapy of choice, and therefore, preoperative localization of insulinomas is essential. Nearly all insulinomas show overexpression of the glucagon‐like peptide‐1 receptor (GLP‐1R), and therefore, radiolabeled GLP‐1 peptide analog exendin‐4 can be used for diagnosis and preoperative localization with nuclear imaging. Here, we present an overview of the development and clinical implementation of exendin‐4–based tracers for single‐photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging of insulinomas, and we address the potential use of this molecule for optical imaging. At last, we discuss the possibilities and pitfalls of the use of exendin‐4–based tracers for therapeutic applications such as peptide receptor radionuclide therapy (PRRT) or targeted photodynamic therapy (tPDT), giving a future outlook on the use of exendin‐4 in insulinoma theranostics.

Subjects

POSITRON emission tomography; SINGLE-photon emission computed tomography; PANCREATIC beta cells; PEPTIDE receptors; GLUCAGON-like peptide-1 receptor; NEUROENDOCRINE tumors; PHOTODYNAMIC therapy

Publication

Journal of Labelled Compounds & Radiopharmaceuticals, 2019, Vol 62, Issue 10, p656

ISSN

0362-4803

Publication type

Academic Journal

DOI

10.1002/jlcr.3750